Insomnia and its associations in patients with recurrent glial neoplasms.
Abstract
BACKGROUND: Patient with neurological disorders and cancer can develop sleep disturbance,
in particular insomnia. Etiology of insomnia is multi-factorial in primary brain tumour
patients with possible causes including corticosteroids, psychoactive medications,
co-morbid psychiatric/medical conditions, and damage to neuronal tissue. FINDINGS:
To understand better insomnia in recurrent glioma patients, a single-center retrospective
analysis was performed looking at recurrent glioma patients from January 2004 to May
2009. Data was extracted and included demographics, clinical factors, psychoactive
medications, and co-morbid symptoms. Presence and absence of insomnia complaints was
evaluated with other co-morbidities using Chi square and Wilcoxon analyses. Records
from 340 recurrent glioma patients were evaluated and 46.8 % (n = 159) indicated presence
of insomnia with 20 % (n = 66) actively using medications for sleep. Use of corticosteroids
were significantly associated with insomnia (p = 0.0003). Age, gender, tumour location,
use of stimulants, antipsychotics, and antidepressants were not significantly associated
with insomnia in recurrent glioma patients. There was a trend towards a possible significant
association with insomnia to fatigue complaints and use of anti-epileptics, p-values
of 0.0501 and 0.0725 respectively. CONCLUSIONS: In conclusion, insomnia is commonly
encountered in patients with recurrent glial tumors. Corticosteroid use is associated
with insomnia in this population. In light of the frequency of insomnia and its associations,
future analysis is warranted into sleep complaints in recurrent glioma patients and
its impact on quality of life.
Type
Journal articlePermalink
https://hdl.handle.net/10161/13036Published Version (Please cite this version)
10.1186/s40064-016-2578-6Publication Info
Robertson, Matthew E; McSherry, Frances; Herndon, James E; & Peters, Katherine B (2016). Insomnia and its associations in patients with recurrent glial neoplasms. Springerplus, 5(1). pp. 823. 10.1186/s40064-016-2578-6. Retrieved from https://hdl.handle.net/10161/13036.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
James Emmett Herndon II
Professor of Biostatistics & Bioinformatics
Current research interests have application to the design and analysis of cancer clinical
trials. Specifically, interests include the use of time-dependent covariables within
survival models, the design of phase II cancer clinical trials which minimize some
of the logistical problems associated with their conduct, and the analysis of longitudinal
studies with informative censoring (in particular, quality of life studies of patients
with advanced cancer).
Katherine Barnett Peters
Associate Professor of Neurosurgery
Dr. Katy Peters, MD Ph.D. FAAN is an associate professor of neurology and neurosurgery
at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke. Her academic medical
career started at Stanford University School of Medicine, receiving an MD and Ph.D.
in Cancer Biology. After completing a neurology residency at Johns Hopkins University
and a fellowship in cognitive neurosciences, Katy joined the PRTBTC as a neuro-oncology
fellow. In 2009, she became a faculty member at
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info